spironolactone has been researched along with naloxone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chatterjee, TK; Das, S; Ganguly, A; Ghosh, JJ | 1 |
| Laorden, ML; Milanés, MV; Navarro-Zaragoza, J | 2 |
1 review(s) available for spironolactone and naloxone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for spironolactone and naloxone
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Role of adrenal steroids on electroacupuncture analgesia and on antagonising potency of naloxone.
Topics: Adrenal Glands; Adrenalectomy; Adrenocorticotropic Hormone; Angiotensin II; Animals; Captopril; Desoxycorticosterone; Dexamethasone; Electric Stimulation Therapy; Male; Mineralocorticoids; Naloxone; Rats; Spironolactone; Time Factors; Transcutaneous Electric Nerve Stimulation | 1984 |
Spironolactone decreases the somatic signs of opiate withdrawal by blocking the mineralocorticoid receptors (MR).
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Enzyme Activation; Hypothalamo-Hypophyseal System; Hypothalamus; Male; Mineralocorticoid Receptor Antagonists; Morphine; Naloxone; Narcotic Antagonists; Norepinephrine; Opioid-Related Disorders; Paraventricular Hypothalamic Nucleus; Phosphorylation; Pituitary-Adrenal System; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 2014 |
Glucocorticoid receptor but not mineralocorticoid receptor mediates the activation of ERK pathway and CREB during morphine withdrawal.
Topics: Analgesics, Opioid; Animals; Cyclic AMP Response Element-Binding Protein; Dopamine; Hormone Antagonists; Male; MAP Kinase Signaling System; Mifepristone; Mineralocorticoid Receptor Antagonists; Morphine; Naloxone; Narcotic Antagonists; Nucleus Accumbens; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 2017 |